Medical Therapy Guidelines

Revision as of 20:35, 27 October 2016 by Dima Nimri (talk | contribs) (Created page with "__NOTOC__ {{Endocarditis}} {{CMG}}; {{AE}}{{DN}} ==2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease== ===Medical Therapy=== {|class="wikita...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Endocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Infective Endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Diagnosis and Follow-up

Medical Therapy

Intervention

Case Studies

Case #1

Medical Therapy Guidelines On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Medical Therapy Guidelines

CDC onMedical Therapy Guidelines

Medical Therapy Guidelines in the news

Blogs on Medical Therapy Guidelines

to Hospitals Treating Medical Therapy Guidelines

Risk calculators and risk factors for Medical Therapy Guidelines

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Medical Therapy

Class I
"1. Appropriate antibiotic therapy should be initiated and continued after blood cultures are obtained with guidance from antibiotic sensitivity data and infectious disease consultants(Level of Evidence: B)"
Class IIa
"1. It is reasonable to temporarily discontinue anticoagulation in patients with IE who develop central nervous system symptoms compatible with embolism or stroke regardless of the other indications for anticoagulation (Level of Evidence: B)"
Class IIb
"1. Temporary discontinuation of VKA anticoagulation might be considered in patients receiving VKA anticoagulation at the time of IE diagnosis (Level of Evidence: B)"
Class III (Harm)
"1. Patients with known VHD should not receive antibiotics before blood cultures are obtained for unexplained fever. (Level of Evidence: C)"